# Phase III Study of SY-5007, a RET Inhibitor, in Patients With Locally Advanced or Metastatic RET Fusion-positive NSCLC

> **NCT06031558** · PHASE3 · RECRUITING · sponsor: **Shouyao Holdings (Beijing) Co. LTD** · enrollment: 120 (estimated)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** SY-5007

## Key facts

- **NCT ID:** NCT06031558
- **Lead sponsor:** Shouyao Holdings (Beijing) Co. LTD
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-06-20
- **Primary completion:** 2024-09-20
- **Final completion:** 2026-06-20
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2023-09-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06031558

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06031558, "Phase III Study of SY-5007, a RET Inhibitor, in Patients With Locally Advanced or Metastatic RET Fusion-positive NSCLC". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT06031558. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*